<DOC>
	<DOCNO>NCT01886469</DOCNO>
	<brief_summary>The main purpose study determine rate extent absorption one modify release formulation amphetamine ( HLD100 ) adolescents child ADHD .</brief_summary>
	<brief_title>A Phase II , Adaptive Trial Design Examining Pharmacokinetic Pharmacodynamic Effects Modified Release Amphetamine ( HLD100 , Formulations B , C E ) ) Adolescents Children With Attention-Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<criteria>Main Inclusion Criteria Male female adolescent ( 1217 year ; Stage 1 ) child ( 611 year ; Stage 2 ) . Diagnosis ADHD confirm KiddieSchedule Affective Disorders Schizophrenia ( KSADS ) . ADHD symptom control stable dose Vyvanse , Adderall XR Dexedrine . Provision inform consent ( parent [ ] legal representative [ ] ) assent ( subject ) patient . Main Exclusion Criteria Comorbid psychiatric diagnosis ( e.g. , psychosis , bipolar disorder ) . History seizures current diagnosis family history Tourette 's disorder . Use prescription drug ( except Vyvanse , Dexedrine Adderall XR ) 14 day overthecounter drug ( except birth control ) 30 day study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>